BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36965173)

  • 1. Multi-institutional experience with COVID-19 convalescent plasma in children.
    Jacquot C; Gordon O; Noland D; Donowitz JR; Levy E; Jain S; Willis Z; Rimland C; Loi M; Arrieta A; Annen K; Drapeau N; Osborne S; Ardura MI; Arora S; Zivick E; Delaney M
    Transfusion; 2023 May; 63(5):918-924. PubMed ID: 36965173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Convalescent plasma in hospitalized pediatric and obstetric coronavirus disease 2019 (COVID-19) patients.
    Ikeda S; Benzi E; Hensch LA; Devaraj S; Hui SR; Gandhi M; Fox KA; Teruya J; Munoz FM
    Pediatr Int; 2022 Jan; 64(1):e15407. PubMed ID: 36326636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfusion reactions associated with COVID-19 convalescent plasma in outpatient clinical trials.
    Huaman MA; Raval JS; Paxton JH; Mosnaim GS; Patel B; Anjan S; Meisenberg BR; Levine AC; Marshall CE; Yarava A; Shenoy AG; Heath SL; Currier JS; Fukuta Y; Blair JE; Spivak ES; Petrini JR; Broderick PB; Rausch W; Cordisco M; Hammel J; Greenblatt B; Cluzet VC; Cruser D; Oei K; Abinante M; Hammitt LL; Sutcliffe CG; Forthal DN; Zand MS; Cachay ER; Kassaye SG; Ram M; Wang Y; Das P; Lane K; McBee NA; Gawad AL; Karlen N; Ford DE; Laeyendecker O; Pekosz A; Klein SL; Ehrhardt S; Lau B; Baksh SN; Shade DM; Casadevall A; Hanley DF; Ou J; Gniadek TJ; Ziman A; Shoham S; Gebo KA; Bloch EM; Tobian AAR; Sullivan DJ; Gerber JM
    Transfusion; 2023 Sep; 63(9):1639-1648. PubMed ID: 37534607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Antibody Kinetics of COVID-19 Convalescent Plasma for the Treatment of Moderate to Severe Cases of SARS-CoV-2 Infection in Pediatric Patients.
    Arrieta A; Galvis AE; Morphew T; Ehwerhemuepha L; Osborne S; Enriquez C; Imfeld K; Hoang J; Nieves D; Ashouri N; Singh J; Nugent D
    Pediatr Infect Dis J; 2021 Jul; 40(7):606-611. PubMed ID: 33967228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Piechotta V; Chai KL; Valk SJ; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD013600. PubMed ID: 32648959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion.
    Wirz OF; Röltgen K; Stevens BA; Pandey S; Sahoo MK; Tolentino L; Verghese M; Nguyen K; Hunter M; Snow TT; Singh AR; Blish CA; Cochran JR; Zehnder JL; Nadeau KC; Pinsky BA; Pham TD; Boyd SD
    Front Immunol; 2021; 12():739037. PubMed ID: 34594341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry.
    De Silvestro G; Marson P; La Raja M; Cattelan AM; Guarnieri G; Monticelli J; Tiberio I; Vianello A; Gandini G; Gessoni G; Fiorin F; Sardella C; Astolfi L; Saia M;
    Eur J Intern Med; 2022 Mar; 97():42-49. PubMed ID: 34980505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical use of Convalescent Plasma in the COVID-19 pandemic: a transfusion-focussed gap analysis with recommendations for future research priorities.
    Al-Riyami AZ; Schäfer R; van den Berg K; Bloch EM; Estcourt LJ; Goel R; Hindawi S; Josephson CD; Land K; McQuilten ZK; Spitalnik SL; Wood EM; Devine DV; So-Osman C
    Vox Sang; 2021 Jan; 116(1):88-98. PubMed ID: 32542847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active surveillance of serious adverse events following transfusion of COVID-19 convalescent plasma.
    Swenson E; Wong LK; Jhaveri P; Weng Y; Kappagoda S; Pandey S; Pritchard A; Rogers A; Ruoss S; Subramanian A; Shan H; Hollenhorst M
    Transfusion; 2022 Jan; 62(1):28-36. PubMed ID: 34677830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study.
    Alsharidah S; Ayed M; Ameen RM; Alhuraish F; Rouheldeen NA; Alshammari FR; Embaireeg A; Almelahi M; Adel M; Dawoud ME; Aljasmi MA; Alshammari N; Alsaeedi A; Al-Adsani W; Arian H; Awad H; Alenezi HA; Alzafiri A; Gouda EF; Almehanna M; Alqahtani S; Alshammari A; Askar MZ
    Int J Infect Dis; 2021 Feb; 103():439-446. PubMed ID: 33285283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Early transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: A structured summary of a study protocol for a randomised controlled trial".
    Teofili L; Landolfi R; Cingolani A; Antinori A; Vecchiet J; Sanguinetti M; Gasbarrini A; Pasciuto T; Orlando N; Lamonica S
    Trials; 2020 Oct; 21(1):875. PubMed ID: 33092632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early high-titer convalescent plasma therapy in patients with moderate and severe COVID-19.
    Fazeli A; Sharifi S; Behdad F; Okati S; Esmaielifar G; Jelveh N; Eshghi P; Mohammadi S
    Transfus Apher Sci; 2022 Apr; 61(2):103321. PubMed ID: 34836825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID 19 convalescent plasma: Is there still a place for CCP?
    Moog R
    Transfus Apher Sci; 2023 Apr; 62(2):103680. PubMed ID: 36870907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.
    Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS
    Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19.
    Sanz C; Nomdedeu M; Pereira A; Sauleda S; Alonso R; Bes M; Brillembourg H; García-Vidal C; Millan A; Martínez-Llonch N; Pirón M; Puerta-Alcalde P; Puig L; Rico V; Soriano A
    Transfusion; 2022 May; 62(5):974-981. PubMed ID: 35338710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial.
    Ortigoza MB; Yoon H; Goldfeld KS; Troxel AB; Daily JP; Wu Y; Li Y; Wu D; Cobb GF; Baptiste G; O'Keeffe M; Corpuz MO; Ostrosky-Zeichner L; Amin A; Zacharioudakis IM; Jayaweera DT; Wu Y; Philley JV; Devine MS; Desruisseaux MS; Santin AD; Anjan S; Mathew R; Patel B; Nigo M; Upadhyay R; Kupferman T; Dentino AN; Nanchal R; Merlo CA; Hager DN; Chandran K; Lai JR; Rivera J; Bikash CR; Lasso G; Hilbert TP; Paroder M; Asencio AA; Liu M; Petkova E; Bragat A; Shaker R; McPherson DD; Sacco RL; Keller MJ; Grudzen CR; Hochman JS; Pirofski LA; ; Parameswaran L; Corcoran AT; Rohatgi A; Wronska MW; Wu X; Srinivasan R; Deng FM; Filardo TD; Pendse J; Blaser SB; Whyte O; Gallagher JM; Thomas OE; Ramos D; Sturm-Reganato CL; Fong CC; Daus IM; Payoen AG; Chiofolo JT; Friedman MT; Wu DW; Jacobson JL; Schneider JG; Sarwar UN; Wang HE; Huebinger RM; Dronavalli G; Bai Y; Grimes CZ; Eldin KW; Umana VE; Martin JG; Heath TR; Bello FO; Ransford DL; Laurent-Rolle M; Shenoi SV; Akide-Ndunge OB; Thapa B; Peterson JL; Knauf K; Patel SU; Cheney LL; Tormey CA; Hendrickson JE
    JAMA Intern Med; 2022 Feb; 182(2):115-126. PubMed ID: 34901997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-Dose Convalescent Plasma for Treatment of Severe COVID-19.
    De Santis GC; Oliveira LC; Garibaldi PMM; Almado CEL; Croda J; Arcanjo GGA; Oliveira ÉAF; Tonacio AC; Langhi DM; Bordin JO; Gilio RN; Palma LC; Santos EV; Haddad SK; Prado BPA; Pontelli MC; Gomes R; Miranda CH; Auxiliadora Martins M; Covas DT; Arruda E; Fonseca BAL; Calado RT
    Emerg Infect Dis; 2022 Mar; 28(3):548-555. PubMed ID: 35081022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Chai KL; Valk SJ; Piechotta V; Kimber C; Monsef I; Doree C; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 Oct; 10():CD013600. PubMed ID: 33044747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.